Sign in

CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company

Olema Oncology, Inc.

Sign in to watch
Ticker
OLMA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
300409740
Phone
(415) 651-3316
Business address
365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
Former names
Olema Pharmaceuticals, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 17 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-06-16 Larson Yi Director Grant or award · Stock Option (right to buy) +21,520 21,520
2023-06-16 Horning Sandra Director Grant or award · Stock Option (right to buy) +21,520 21,520
2023-06-16 CLARK IAN T Director Grant or award · Stock Option (right to buy) +21,520 21,520
2023-06-16 Graham G. Walmsley Director Grant or award · Stock Option (right to buy) +21,520 21,520
2023-06-16 Hrustanovic Gorjan Director Grant or award · Stock Option (right to buy) +21,520 21,520
2023-06-16 BUTITTA CYNTHIA M Director Grant or award · Stock Option (right to buy) +21,520 21,520
2023-06-16 RAPPAPORT ANDREW Director Grant or award · Stock Option (right to buy) +21,520 21,520
2023-06-16 BVF PARTNERS L P/IL Director Grant or award · Stock Option (Right to buy) +21,520 21,520
2023-06-08 Harmon Cyrus Director Sale −10,000 $6.30 $63K 1,038,714
2023-06-06 Harmon Cyrus Director Sale −5,000 $6.30 $31K 1,048,714
2023-06-05 Harmon Cyrus Director Sale −5,000 $6.05 $30K 1,053,714
2023-04-06 Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. Purchase +10,000 396,197
2023-02-01 Zojwalla Naseem Chief Medical Officer Grant or award · Stock Option (Right to Buy) +150,000 150,000
2023-02-01 Moriarty John B EVP, Ch. Legal Officer & Sec. Grant or award · Stock Option (Right to Buy) +150,000 150,000
2023-02-01 Myles David C. Chief Development Officer Grant or award · Stock Option (Right to Buy) +150,000 150,000
2023-02-01 Kovacs Shane William Charles Ch. Operating & Financial Off. Grant or award · Stock Option (Right to Buy) +200,000 200,000
2023-02-01 Horn Kinney Chief Business Officer Grant or award · Stock Option (Right to Buy) +150,000 150,000
2023-02-01 Bohen Sean President and CEO Grant or award · Stock Option (Right to Buy) +550,000 550,000
2023-02-01 Harmon Cyrus Chief Research Officer Grant or award · Stock Option (Right to Buy) +150,000 150,000
2022-09-21 Bohen Sean PRESIDENT AND CEO Purchase +20,000 74,279

Page 13 of 21 · 402 trades